News

Kinarus Therapeutics and the Great Health Companion Group (GHCG) in China are exploring a partnership to fund further development of KIN001, Kinarus’ potential treatment for idiopathic pulmonary fibrosis (IPF). Switzerland-based Kinarus and GHCG, a subsidiary of global China conglomerate Hakim Unique Group, are also looking into ways to…

TXR-1002, Aria Pharmaceuticals’ investigational candidate for idiopathic pulmonary fibrosis (IPF), effectively prevented the buildup of scar tissue, or fibrosis, in the lungs of a rat model of the disease. Its effectiveness was comparable to that of the approved IPF therapy, Ofev (nintedanib) and was consistent with findings…

PLN-74809, an oral treatment candidate for idiopathic pulmonary fibrosis (IPF), will now be called bexotegrast, its maker, Pliant Therapeutics, announced in a corporate update. The change came after the International Nonproprietary Names Expert Group selected bexotegrast as the unique generic, or nonproprietary, name for the experimental therapy. The company also announced…

Bridge Biotherapeutics has launched a Phase 2a clinical trial to assess the safety, tolerability, and effectiveness of BBT-877 in people with idiopathic pulmonary fibrosis (IPF). The trial (NCT05483907) is expected to enroll around 120 IPF patients, ages 40 and older, in 50 clinical sites in North America,…

The Pulmonary Fibrosis Foundation (PFF) is welcoming applications for its 2023 PFF Scholars program, which helps fund early-stage investigators developing research to improve the outcomes of people with pulmonary fibrosis (PF). Each investigator will receive a two-year research grant totaling $100,000, which is an increase of $25,000 a scholar…

Following the successful completion of preclinical studies, Saniona is now ready to initiate the regulatory process needed to start testing SAN903 — its therapy candidate for idiopathic pulmonary fibrosis (IPF) and other disorders — in Phase 1 human trials. “Preclinical data for SAN903 are very compelling,” Thomas Feldthus,…

Real-world data support the safety profile of the anti-fibrotic medications Esbriet (pirfenidone) and Ofev (nintedanib) in people with idiopathic pulmonary fibrosis (IPF), according to a new study. More than half of patients experienced treatment-related adverse events, the majority being non-severe gastrointestinal symptoms. Rare cases of serious heart-related…

Boehringer Ingelheim has enrolled the first patient in FIBRONEER-IPF, a Phase 3 clinical trial evaluating the efficacy, safety, and tolerability of BI 1015550, an investigational therapy for people with idiopathic pulmonary fibrosis (IPF). The trial is part of the FIBRONEER global program, which also includes FIBRONEER-ILD, a similar Phase…

AbbVie’s portfolio of antibodies for the potential treatment of idiopathic pulmonary fibrosis (IPF) now includes DJS-002 — a first-in-class antibody directed against lysophosphatidic acid receptor-1 (LPAR1), a protein thought to drive the progression of IPF and other fibrotic diseases. This was made possible by AbbVie’s estimated $250 million acquisition of…

A test by Veracyte can be used to predict which patients with interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF), are more likely to experience progressive decline in their lung function, according to new data. Called the Envisia Genomic Classifier, the test works by identifying the genomic…